Focused &
Specialized

Clinical trial sponsors working in oncology, hematology, IBD, infectious diseases, multiple sclerosis, and many rare diseases, rely on PSI’s guidance and experience, knowing we’re specialized and committed to delivering some of the most complex clinical projects in the industry.

Core Therapeutic Areas

Inflammatory Bowel Diseases (IBD)

Crohns’ Disease, Ulcerative Colitis, and other IBDs.

Oncology

Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and other Oncology indications.

Hematology

Multiple Myeloma, Lymphomas, Leukemias, and other oncohematological indications.

Infectious Diseases

Antimicrobial and Antifungal infections and other ID.

Multiple Sclerosis

Multiple Sclerosis, Spasticity, and other neurological indications.

Rare Diseases

Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).

The PSI Advantage

PSI CRO has received 2024 CRO Leadership Awards in the categories of Expertise, Quality, Compatibility, and Reliability in the Overall (combined Big and Small Pharma) respondent group. This is the seventh consecutive year that PSI has received leadership awards presented by Clinical Leader and Life Science Connect based on research conducted by ISR. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.

PSI wins CRO Leadership Awards for Expertise, Compatibility, Quality, and Reliability

PSI was flexible to meet the various challenges in clinical trial conduct. The rapid enrollment of patients and the quick study close out allowed on-time study completion.

Chief Medical Officer